Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
80.91
USD
|
-1.53%
|
|
-8.71%
|
-16.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,187
|
15,918
|
16,220
|
19,234
|
18,162
|
15,355
|
-
|
-
|
Enterprise Value (EV)
1 |
14,870
|
15,643
|
15,778
|
19,592
|
18,176
|
14,566
|
13,999
|
13,146
|
P/E ratio
|
-650
x
|
19.4
x
|
-252
x
|
138
x
|
111
x
|
44.7
x
|
31.9
x
|
24.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.91
x
|
8.56
x
|
8.79
x
|
9.18
x
|
7.51
x
|
5.6
x
|
4.96
x
|
4.45
x
|
EV / Revenue
|
8.73
x
|
8.41
x
|
8.55
x
|
9.35
x
|
7.51
x
|
5.32
x
|
4.52
x
|
3.81
x
|
EV / EBITDA
|
3,070
x
|
229
x
|
614
x
|
77.9
x
|
69.2
x
|
28.7
x
|
18
x
|
13
x
|
EV / FCF
|
-154
x
|
-540
x
|
75.5
x
|
357
x
|
290
x
|
25.5
x
|
18.9
x
|
14
x
|
FCF Yield
|
-0.65%
|
-0.19%
|
1.32%
|
0.28%
|
0.34%
|
3.92%
|
5.3%
|
7.15%
|
Price to Book
|
4.87
x
|
3.88
x
|
3.8
x
|
4.25
x
|
3.67
x
|
2.83
x
|
2.49
x
|
2.15
x
|
Nbr of stocks (in thousands)
|
179,625
|
181,530
|
183,593
|
185,849
|
188,368
|
189,777
|
-
|
-
|
Reference price
2 |
84.55
|
87.69
|
88.35
|
103.5
|
96.42
|
80.91
|
80.91
|
80.91
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,704
|
1,860
|
1,846
|
2,096
|
2,419
|
2,740
|
3,095
|
3,449
|
EBITDA
1 |
4.843
|
68.44
|
25.7
|
251.5
|
262.5
|
506.9
|
778.1
|
1,013
|
EBIT
1 |
-100.5
|
-36.76
|
-82.34
|
149.6
|
158.1
|
449
|
692
|
938.2
|
Operating Margin
|
-5.9%
|
-1.98%
|
-4.46%
|
7.14%
|
6.54%
|
16.39%
|
22.36%
|
27.2%
|
Earnings before Tax (EBT)
1 |
-94.81
|
-42.32
|
-75.35
|
149.6
|
188.6
|
468.5
|
663.9
|
880.9
|
Net income
1 |
-23.85
|
859.1
|
-64.08
|
141.6
|
167.6
|
357.7
|
491.2
|
656.6
|
Net margin
|
-1.4%
|
46.18%
|
-3.47%
|
6.75%
|
6.93%
|
13.06%
|
15.87%
|
19.04%
|
EPS
2 |
-0.1300
|
4.530
|
-0.3500
|
0.7500
|
0.8700
|
1.809
|
2.533
|
3.247
|
Free Cash Flow
1 |
-96.76
|
-28.95
|
209
|
54.94
|
62.57
|
570.7
|
742.1
|
940.3
|
FCF margin
|
-5.68%
|
-1.56%
|
11.32%
|
2.62%
|
2.59%
|
20.83%
|
23.98%
|
27.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
813.13%
|
21.84%
|
23.84%
|
112.58%
|
95.37%
|
92.82%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
38.81%
|
37.32%
|
159.54%
|
151.07%
|
143.21%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
408.7
|
449.8
|
519.4
|
533.8
|
505.3
|
537.5
|
596.4
|
595.3
|
581.3
|
646.2
|
648.8
|
660.7
|
690.7
|
741.8
|
727.3
|
EBITDA
1 |
-26.38
|
-
|
164.7
|
64.42
|
22.38
|
0.053
|
85.77
|
-
|
51.35
|
41.08
|
115.8
|
101
|
79.16
|
127.6
|
-
|
EBIT
1 |
-53.22
|
-65.88
|
137.3
|
39.15
|
-2.417
|
-24.5
|
59.35
|
58.87
|
25.66
|
14.22
|
88.46
|
78.5
|
107.6
|
132.8
|
141.1
|
Operating Margin
|
-13.02%
|
-14.65%
|
26.44%
|
7.33%
|
-0.48%
|
-4.56%
|
9.95%
|
9.89%
|
4.41%
|
2.2%
|
13.63%
|
11.88%
|
15.58%
|
17.9%
|
19.39%
|
Earnings before Tax (EBT)
1 |
-46.16
|
-66.57
|
134.2
|
34.85
|
-1.904
|
-17.56
|
56.76
|
70.81
|
41.67
|
19.33
|
105.5
|
93.75
|
117
|
139.3
|
142.8
|
Net income
1 |
-36.49
|
-57.9
|
120.8
|
27.66
|
-6.652
|
-0.249
|
50.85
|
56.04
|
40.38
|
20.38
|
88.66
|
73.14
|
93.37
|
109.9
|
109.2
|
Net margin
|
-8.93%
|
-12.87%
|
23.26%
|
5.18%
|
-1.32%
|
-0.05%
|
8.53%
|
9.41%
|
6.95%
|
3.15%
|
13.66%
|
11.07%
|
13.52%
|
14.82%
|
15.01%
|
EPS
2 |
-0.2000
|
-0.3200
|
0.6300
|
0.1500
|
-0.0400
|
-
|
0.2700
|
0.2900
|
0.2100
|
0.1100
|
0.4600
|
0.3500
|
0.4720
|
0.5658
|
0.5397
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/27/21
|
2/23/22
|
4/27/22
|
8/3/22
|
10/26/22
|
2/27/23
|
4/26/23
|
7/31/23
|
11/1/23
|
2/22/24
|
4/24/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
358
|
13.2
|
-
|
-
|
-
|
Net Cash position
1 |
318
|
276
|
443
|
-
|
-
|
789
|
1,356
|
2,208
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
1.425
x
|
0.0501
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-96.8
|
-28.9
|
209
|
54.9
|
62.6
|
571
|
742
|
940
|
ROE (net income / shareholders' equity)
|
-0.78%
|
23.8%
|
-1.53%
|
3.19%
|
3.51%
|
8.96%
|
10.9%
|
12.6%
|
ROA (Net income/ Total Assets)
|
-0.52%
|
16.3%
|
-1.08%
|
2.29%
|
2.54%
|
6.17%
|
8.69%
|
9.71%
|
Assets
1 |
4,559
|
5,269
|
5,926
|
6,190
|
6,608
|
5,801
|
5,653
|
6,765
|
Book Value Per Share
2 |
17.40
|
22.60
|
23.20
|
24.40
|
26.30
|
28.60
|
32.50
|
37.70
|
Cash Flow per Share
2 |
-
|
0.4500
|
1.670
|
0.9300
|
0.8300
|
5.870
|
4.490
|
6.420
|
Capex
1 |
145
|
114
|
95.6
|
121
|
96.7
|
111
|
115
|
118
|
Capex / Sales
|
8.51%
|
6.14%
|
5.18%
|
5.77%
|
4%
|
4.06%
|
3.71%
|
3.41%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
80.91
USD Average target price
110
USD Spread / Average Target +35.90% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.09% | 15.35B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -17.69% | 11.6B | | -43.00% | 11.51B | | -9.14% | 11.95B | | +5.24% | 8.71B | | -8.42% | 8.12B |
Biopharmaceuticals
|